CB-5945

DRUG4 trials

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

Opioid-Induced Constipation

Phase 3

Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

TerminatedNCT01696643

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Opioid-Induced Constipation

Start: 2012-10-12End: 2014-07-21Updated: 2018-11-15

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

TerminatedNCT01901302

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Opioid-Induced Constipation

Start: 2013-05-20End: 2014-02-13Updated: 2018-11-15

The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

TerminatedNCT01901341

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Opioid-Induced Constipation

Start: 2013-07-02End: 2014-02-13Updated: 2018-11-15

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

TerminatedNCT01901328

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Opioid-Induced Constipation

Start: 2013-04-07End: 2014-02-13Updated: 2018-11-15